


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-34. (cancelled)

35. (currently amended) An inclusion complex of a compound according to formula I ~~claim 21,~~ with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, and said formula I being:



wherein,

m represents an integer equal to 5, 6 or 7;

n and n' represent an integer from 1 to 5, n and n'


being identical or different;

A represents a hydrogen atom, an acyl, an alkyl, a hydroxyalkyl or a sulphaalkyl group of 1 to 16 carbon atoms, each A being identical or different;


X represents O or S,

Y represents a group selected from the group consisting of:


(i) an $-NR_1-$ group, wherein R_1 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms, such that said compound corresponds to formula (I-a):



(ii) an amide group of formula $-NH-CO-(CH_2)_q-NR_1-$, wherein q represents an integer from 1 to 5 and R_1 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms, such that said compound corresponds to formula (I-b):




(iii) a cysteaminy group of formula $-S-(CH_2)_r-NR_1-$, wherein r represents an integer from 2 to 5 and R_1 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms, so that said compound corresponds to formula (I-c):



W represents CH or N; and

Z represents a group selected from the group consisting

of:




a carbamate substituent of formula


an amine substituent of formula $\text{---}(\text{---})_p\text{---NHR}_2$,



a quaternary ammonium group of formula $\left(\text{---} \right)_p \text{N}^+(\text{R}_2)_3$,




a urea or thiourea substituent of formula:



a group of formula $\begin{array}{c} \text{X'} \\ \parallel \\ \diagup \quad \diagdown \\ \text{NHR} \end{array}$, and



one of a group according to formula C(=O)OR₁, a group according to formula C(=O)R₂, and a group carrying the amine, ammonium quaternary urea or thiourea functionalities, of respective formulae:



p representing an integer from 0 to 5, when W
represents CH, and from 2 to 5, when W represents N,

X' representing 0 or S,

R₂ representing a hydrogen atom or an alkyl group
comprising from 1 to 6 carbon atoms,

R₃ representing a substituent allowing the hydrolysis
of the carbamate group in order to release the amine function,
and

R representing one of:

(i) a substituent selected from the group consisting of a hydrogen atom, a linear or branched alkyl group of 1 to 12 carbon atom, an aromatic group, and an aromatic group carrying at least one substituent on the aromatic ring, said at least one substituent selected from the group consisting of methyl, ethyl, chlorine, bromine, iodine, nitro, hydroxyl, methoxyl and acetamido substituents, and

(ii) a biological recognition element selected from the group consisting of an amino acid, a peptide, a monosaccharide, an oligosaccharide, and a multiplication element with branchings, said branchings selected from the group consisting of:

(a) glucide groups, which can be identical or different, and

(b) molecular structure allowing detection by fluorescent or radioactive visualization.

36. (currently amended) ~~[[An]] The inclusion complex of a compound according to claim [[21]] 35, with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, characterized in that wherein the pharmacologically active molecule is a ditopic molecule.~~

37. (currently amended) ~~[[An]]~~ The inclusion complex of ~~a compound~~ according to claim ~~[[21]]~~ 35, ~~with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, characterized in that~~ wherein the pharmacologically active molecule is an antineoplastic agent.

38. (cancelled)

39. (currently amended) A pharmaceutical composition comprising ~~[[an]]~~ the inclusion complex of ~~a compound~~ according to claim ~~[[21]]~~ 35, ~~with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, in~~ association with a pharmacologically acceptable vehicle.

40. (cancelled)

41. (currently amended) A pharmaceutical composition comprising ~~[[an]]~~ the inclusion complex of ~~a compound~~ according to claim ~~[[21]]~~ 35, ~~with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, in~~

association with a pharmacologically acceptable vehicle, in the form of aqueous solution.

42. (cancelled)

43. (currently amended) A pharmaceutical composition comprising [(an)] the inclusion complex of a compound according to claim [[21]] 35, ~~with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, in association with a pharmacologically acceptable vehicle, characterized in that it contains wherein said complex is per unit dose approximately 100 mg to approximately 750 mg per unit dose of said pharmaceutical composition of one of said complex.~~